Table 1.
Principal characteristics of the Phase II studies.
| References | Country | Phase | Type of publication | Randomised vs. placebo | No. of patients | Grade | Primitive site | ECOG PS | Biomarker evaluation | Setting |
|---|---|---|---|---|---|---|---|---|---|---|
| Ahn et al. (23) | Asia | II | Full Text | No | 37 | G1 G2 G3 |
Pancreas GI Lung Unknown Other |
0–1 | No | Metastatic only |
| Phan et al. (24) | US | II | Full Text | No | 52 | G1 G2 |
GI Pancreas |
0–1 | No | Metastatic/locally advanced |
| Grande et al. (25) | Europe | II | Full Text | No | 44 | G1 G2 |
Pancreas GI Lung Unknown Other |
0–1 | Yes | Metastatic/locally advanced |
| Bergsland et al. (26) | US | II | Abstract | Yes | 171 | G1 G2 UK |
Pancreas GI Lung Other |
0–1 | Yes | Metastatic/locally advanced |
ECOG PS, Eastern Cooperative Oncology Group Performance Status; GI, gastrointestinal.